PharmaCyte Biotech, Inc. (PMCB)

Company Overview
Nuvilex is an innovative company which aims at ionitiating a paradigm shift, generating revenue at the same time as creating cancer and other cell related solutions to treat important human diseases, such as pancreatic cancer while retaining our connections to natural products. The present effort underway will give rise to dramatic advances in cancer therapy and benefit millions of people worldwid
read more

Watch the video to learn about the probability of PharmaCyte Biotech, Inc. (PMCB) Chart Signal as of Jul 23, 2016

Hotstocked Precision will calculate the probabilities of PharmaCyte Biotech, Inc. (PMCB)

Rating:
Size: 656KB
Version: 1.1
Platform: Win/Mac
Downloads: 800,000+
FREE DOWNLOAD

QUOTE

As of 07:10PM EDT July 23, 2016
$ 0.051   -0 (-2.86%)
Today's Open: 0.0535 Previous Close: 0.0525
Today's High: 0.0535 Volume: 3,540,805
Today's Low: 0.0501 Avg Vol: 1,722,882
52 Week High: 0.13 Bid (size): 0
52 Week Low: 0.0385 Ask (size): 0

COMPANY INFO

To see the headquarters in Google Street View &trade, drag this yellow guy: over to the red pointer:

Contact Information:

Business Address: Meadows Corporate Park I, 12510 Prosperity Boulevard, Silver Spring, MD 20904, United States
Mailing Address: -
Phone: 240-696-6859
Fax: -
Website: http//www.nuvilex.com

Company Details:

Symbol: PMCB
SIC: -
State location: MD
Sector: -
State of Inc: NV
Employees: 1
Type: -

Key executives:

Name Age Position
2016
Dr. Gerald W. Crabtree 2016 COO
Patricia Gruden 2016 Chairman of the Board of Directors and CFO
Robert F. Ryan 2016 President, CEO

Watch the video to learn about the probability of PharmaCyte Biotech, Inc. (PMCB) Chart Signal as of Jul 23, 2016

This free program will calculate the probabilities of PharmaCyte Biotech, Inc. (PMCB) stock chart

Rating: Platform: Win/Mac
Price: FREE Version: 1.1
Size: 656KB Downloads: 800,000+
FREE DOWNLOAD

LATEST ARTICLES

Pharmacyte Biotech Inc. (OTCMKTS:PMCB) Loses Ground Again July 22, 2016

Pharmacyte Biotech Inc. (OTCMKTS:PMCB) took a serious step down when it became clear that it will delay its much anticipated 10-K report – and yesterday it lost all the ground it had managed to regain after that point in time. read more

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Surges July 13, 2016

Pharmacyte Biotech Inc (OTCMKTS:PMCB) has had a hard time last month. After managing to keep its value around 7 cents per share for quite some time we saw the ticker begin to slide down the charts and lose a significant amount of altitude. read more

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Scuttles Towards 52-Week Lows February 24, 2016

After a couple of months of sideways trading, yesterday Pharmacyte Biotech Inc (OTCMKTS:PMCB) took another big step down the charts and hit its lowest closing price for the new year. By the bell PMCB was another 7.9% down, at $0.054 per share on volume ... read more

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Files Restated Reports, Drops January 21, 2016

This Tuesday Pharmacyte Biotech Inc (OTCMKTS:PMCB) put up the restated financial reports the company announced were coming earlier. Yesterday the ticker dropped some 7% down to $0.067 per share on daily volume that went back up in the millions. read more

LATEST STOCK PROMOTIONS

PMCB_--_PharmaCyte_Biotech_CEO_Interviews_with_SCN_at_NASDAQ Jun 29, 2016, 09:00

  PharmaCyte CEO Interviews with Small Cap Nation at NASDAQ. View this email in your browser PharmaCyte Biotech CEO Interviews at NASDAQ with Small Cap Nation & Analyst Kevin Baker of Baker Research Group   In the 2 videos below PharmaCyte Biotech's (OTCQB: PMCB) CEO Kenneth Waggoner discusses the company’s upcoming Phase 2b clinical trial in advanced pancreatic read more

Promoter: Stock Market Media Group Paying Party: No Third Party Max Profit: 15.46% Gain at close: Pending
Stock: pmcb Compensation: No compensation Avg $ Volume for Period: UNKNOWN

PMCB_--_Valuing_PharmaCyte_Biotech's Mar 10, 2016, 08:29

    Valuing PharmaCyte Biotech's New Treatment Option for Pancreatic Cancer   Is this email not displaying correctly? View it in your browser.   Valuing PharmaCyte Biotech's New Treatment Option for Pancreatic Cancer    As PharmaCyte Biotech (OTCQB – PMCB - $0.0625) moves closer to its clinical trial in pancreatic cancer, we will be bringing our subscribers read more

Promoter: Stock Market Media Group Paying Party: No Third Party Max Profit: 5.43% Gain at close: Pending
Stock: pmcb Compensation: No compensation Avg $ Volume for Period: UNKNOWN

The Guide and PMCB Nov 30, 2015, 08:45

  Good morning!   Hope everyone had an enjoyable Thanksgiving weekend. Which sectors will be on fire in the weeks ahead? Is the small cap segment about to break out? The four themes in this week’s Guide include:   ⇒ See which sectors could produce the best returns, moderate returns, and which ones to avoid ⇒ Why small stocks are about to break out and are set to bust through the closing read more

Promoter: Goldman Small Cap Research Paying Party: UNKNOWN Max Profit: 21.93% Gain at close: Pending
Stock: pmcb Compensation: $22,000 Avg $ Volume for Period: UNKNOWN

Nuvilex, Inc. (NVLX) MESSAGE BOARD

Post # Subject Re Name Date
1 YGE=UP because it repaid $110ml debt on... 0
2 Such a deep anewsr! GD&RVVF 0
3 I love these areltics. How many words can... 0
4 Well, I think the Fed has to do a lot... 0
5 I just love how optimistic Jim Cramer and... 0
6 Dear Minamar,Can you give me some more... 0
7 Well mamiadcaa nuts, how about that. 0
8 I hope so 0
9 I'm a Dollarniare now! The scams on otc... 0
10 yes we are ging to be millionaires but it... 1
11 chemo kills weed does not 0
12 What happened to this stock today? It's... 0
13 Oh what happened? 2
14 Tanking like a ROCK!! Alpha Articles out!!! 4
15 FDA possible approval response to NVLX... 1
16 Yes it can 0
17 Man! I'd personally write some options... 0
18 20 Ducats? You jest my dear buffoon! 0
19 Oh Sheeheeheeheet! NVLX is fo' real ?... 0
20 50:1 split? Ha ha 0